Over the last years, more and more tau-treatments are being assessed in mouse models for their potential to treat Alzheimer’s disease. One of the key challenges with many of the tau mouse models is the need for large numbers of animals due to their intrinsic variability.
Tau.P301S model available at reMYND’s CRO for efficacy testing of Alzheimer treatments
reMYND’s Tau.P301L mice used to demonstrate efficacy of antibody treatment on behaviour and pathological read-outs
In the last several years, Tau-directed therapies have gained more interest as a strategy for treating Alzheimer’s Disease.
BMS publishes paper in collaboration with reMYND showing dose-dependent effects of donepezil on brain Abeta and cognition in MWM
We would like to bring to your attention a recent publication titled “Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease”.
Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment
Press release | Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment
reMYND launches a project aimed at improving the predictability of preclinical Alzheimer models as part of the prestigious Marie-Curie International Training Network NPlast
Press release | reMYND NV announced today its project in NPlast, a prestigious International Training Network funded by the European Commission that is to be launched April 27-28th 2012 at the Leibniz-Institut für Neurobiologie in Magdeburg, Germany.